Co-Authors
This is a "connection" page, showing publications co-authored by Timothy Pardee and Leslie Ellis.
Connection Strength
1.240
-
Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Efficacy of 10-day decitabine in acute myeloid leukemia. Leuk Res. 2021 Apr; 103:106524.
Score: 0.192
-
Seegars MB, Woods R, Ellis LR, Bhave RR, Howard DS, Manuel M, Dralle S, Lyerly S, Powell BL, Pardee TS. A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia. J Hematol. 2021 Feb; 10(1):1-7.
Score: 0.192
-
Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 01; 24(9):2060-2073.
Score: 0.156
-
Ahmed T, Koch AL, Isom S, Klepin HD, Bishop JM, Ellis LR, Berenzon D, Howard D, Lyerly S, Powell BL, Pardee TS. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leuk Res. 2017 11; 62:51-55.
Score: 0.152
-
Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015 Sep; 39(9):945-9.
Score: 0.130
-
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014 Oct 15; 20(20):5255-64.
Score: 0.123
-
Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014 Jan; 93(1):47-55.
Score: 0.116
-
Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, Bhave RR, Geiger AM, Williamson JD, Kritchevsky S, Klepin HD. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020 12 03; 136(23):2715-2719.
Score: 0.047
-
Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J Geriatr Oncol. 2020 04; 11(3):410-416.
Score: 0.042
-
Klepin HD, Tooze JA, Pardee TS, Ellis LR, Berenzon D, Mihalko SL, Danhauer SC, Rao AV, Wildes TM, Williamson JD, Powell BL, Kritchevsky SB. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. J Am Geriatr Soc. 2016 10; 64(10):1988-1995.
Score: 0.035
-
Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013 May 23; 121(21):4287-94.
Score: 0.028
-
Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011 Oct; 59(10):1837-46.
Score: 0.025